Every day of the past year, we’ve been working diligently toward making our goal of doubling pancreatic cancer survival by 2020 a reality.
As our fight against pancreatic cancer gains momentum, we are proud of the impact we’ve made over the last 14 years, but we are particularly proud of the progress we’ve made in Fiscal Year 2012-13. Since our last report, our supporters — volunteers, survivors, donors, advocates, scientists and healthcare professionals — have not only grown in numbers, giving additional strength to the cause, but their actions have made a real difference in moving the mission of the organization forward.
The year began auspiciously with President Obama signing the Recalcitrant Cancer Research Act into law. The bill’s passage
Defeating pancreatic cancer has at last become a matter of national will and political commitment.
makes pancreatic cancer a national priority. In addition, not only are more scientists studying pancreatic cancer and receiving funding from our growing pool of research grants, the communication and collaboration among these committed individuals are also increasing. The Pancreatic Cancer Action Network has been instrumental in facilitating this vital collaboration among researchers at diverse institutions and with various areas of expertise.
Determination and perseverance led to the passage of the Recalcitrant Cancer Research Act in January 2013.
True heroes on the front lines are working with us every day to change the course of history for pancreatic cancer.
Meanwhile, our unrelenting volunteers who support the organization in significant ways through events and awareness-raising efforts have grown our affiliate base to nearly 60 robust affiliates nationwide.
These committed volunteers vastly increase the influence of our network. Everywhere, you can find evidence of their impact when droves of purple-clad individuals turn out for volunteer-led PurpleStride walks, runs and rides.
At our Southern California national office, we’ve been making strides through our PALS (Patient and Liaison Services) team by putting thousands of patients in touch with cutting-edge research through potential clinical trial opportunities as well as providing disease-specific information about diagnosis, treatment, support resources and other related topics.
The report that follows provides detailed accounts from the front lines, where our true heroes — volunteers, survivors, donors, advocates, scientists and healthcare professionals — work tirelessly toward our goal of doubling pancreatic cancer survival by 2020. We have no illusions. It is, to be sure, still an uphill push. But with growing momentum propelling us forward, more and more supporters are drawn to our cause, not because it is easy, but because it promises to change the lives of the people they love and many more who will benefit from their selfless commitment.
Julie Fleshman, JD, MBA President and CEO